BioNexus Gene Lab (BGLC) Return on Invested Capital (2019 - 2022)

BioNexus Gene Lab (BGLC) has 4 years of Return on Invested Capital data on file, last reported at 0.03% in Q4 2022.

• For the quarter ending Q4 2022, Return on Invested Capital fell 7.0% year-over-year to 0.03%; the trailing twelve-month figure through Dec 2022 stood at 0.03% (down 7.0% YoY), and the FY2021 full-year result was 0.17%, down 1.0% from the prior year.
• Return on Invested Capital fell to 0.03% in Q4 2022, from 0.01% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.05% in Q3 2020 to a low of 0.03% in Q4 2022.
• A 4-year average of 0.02% and a median of 0.02% in 2022 frame the typical range for Return on Invested Capital.
• Across the five-year window, Return on Invested Capital climbed 6 bps in 2020 and dropped 7 bps in 2022, its largest moves.
• Tracing BGLC's Return on Invested Capital over 4 years: stood at 0.01% in 2019, then surged by 431 bps to 0.05% in 2020, then declined by 7 bps to 0.04% in 2021, then slumped by 158 bps to 0.03% in 2022.
• Business Quant data shows BGLC's Return on Invested Capital at 0.03% in Q4 2022, 0.01% in Q3 2022, and 0.02% in Q2 2022.